<?xml version='1.0' encoding='utf-8'?>
<document id="25459938"><sentence text="Plasma protein binding, pharmacokinetics, tissue distribution and CYP450 biotransformation studies of fidarestat by ultra high performance liquid chromatography-high resolution mass spectrometry." /><sentence text="Fidarestat, an aldose reductase inhibitor, has been used for the treatment of the diabetic associated complications such as retinopathy, neuropathy and nephropathy"><entity charOffset="0-10" id="DDI-PubMed.25459938.s2.e0" text="Fidarestat" /><entity charOffset="15-21" id="DDI-PubMed.25459938.s2.e1" text="aldose" /><pair ddi="false" e1="DDI-PubMed.25459938.s2.e0" e2="DDI-PubMed.25459938.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25459938.s2.e0" e2="DDI-PubMed.25459938.s2.e1" /></sentence><sentence text=" To better understand the metabolism and pharmacokinetics of fidarestat, we have evaluated plasma protein binding, pharmacokinetics, tissue distribution of the drug and its conjugated metabolites and CYP450 biotransformation by liquid chromatography-high resolution mass spectrometry" /><sentence text=" Effective chromatographic separation of fidarestat and hydrochlorothiazide (IS) in rat plasma and tissues was achieved on Hypersil gold C-18 column in an isocratic elution mode"><entity charOffset="41-51" id="DDI-PubMed.25459938.s4.e0" text="fidarestat" /><entity charOffset="56-75" id="DDI-PubMed.25459938.s4.e1" text="hydrochlorothiazide" /><entity charOffset="77-79" id="DDI-PubMed.25459938.s4.e2" text="IS" /><pair ddi="false" e1="DDI-PubMed.25459938.s4.e0" e2="DDI-PubMed.25459938.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25459938.s4.e0" e2="DDI-PubMed.25459938.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25459938.s4.e0" e2="DDI-PubMed.25459938.s4.e2" /><pair ddi="false" e1="DDI-PubMed.25459938.s4.e1" e2="DDI-PubMed.25459938.s4.e1" /><pair ddi="false" e1="DDI-PubMed.25459938.s4.e1" e2="DDI-PubMed.25459938.s4.e2" /></sentence><sentence text=" For detection, a high-resolution Orbitrap mass spectrometer with heated electrospray ionization inlet in the negative ion mode was used" /><sentence text=" High-resolution extracted ion chromatograms for each analyte were obtained by processing the full-scan MS mode with 5 ppm mass tolerance" /><sentence text=" The impact of plasma protein binding with the drug and conjugated metabolites of the drug on pharmacokinetics has been determined" /><sentence text=" The study indicated that 9" /><sentence text="5% of free form of fidarestat may be pharmacologically active and the Cmax for free fidarestat was found to be 80" /><sentence text="30 ± 6" /><sentence text="78 ng/mL" /><sentence text=" The AUC0-t and AUC0-∞ were found to be 185" /><sentence text="46 ± 32 and 195" /><sentence text="92 ± 15" /><sentence text="06 ng h/mL, respectively" /><sentence text=" Among tissues, the maximum observed distribution was found to be in kidney followed by liver and heart" /><sentence text=" Docking experiments and in vitro CYP450 reaction phenotyping revealed that two CYP1A2 and CYP2D6 are involved in the phase I metabolism of fidarestat"><entity charOffset="140-150" id="DDI-PubMed.25459938.s17.e0" text="fidarestat" /></sentence><sentence text=" Oxidative deamination and N/O glucuronidation are the major phase I and phase II metabolites, respectively"><entity charOffset="27-28" id="DDI-PubMed.25459938.s18.e0" text="N" /></sentence><sentence text=" In vitro CYP450 inhibition assay of fidarestat for drug-drug interaction showed weak inhibition and may not alter pharmacokinetics, distribution or clearance of other co-administered drug" /><sentence text="" /></document>